Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit
Rhea-AI Summary
Regulus Therapeutics (Nasdaq: RGLS), a biopharmaceutical company specializing in microRNA-targeted medicine development, has announced its participation in the 2025 Oppenheimer Innovation on the Island Biotech Summit.
CEO Jay Hagan will deliver a presentation on Wednesday, April 9th at 11:32 a.m. ET. Investors and interested parties can access both the live event and replay through the company's investor relations website at https://ir.regulusrx.com/events. The presentation recording will remain accessible for 90 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction – RGLS
In the trading session that priced this news, RGLS gained 12.00%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The live event and replay of the presentation will be available under "Events and Presentations" through the investor relations section of the Company's website at https://ir.regulusrx.com/events and archived for 90 days following the presentation date.
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. Regulus maintains its corporate headquarters in San Diego, CA.
View original content to download multimedia:https://www.prnewswire.com/news-releases/regulus-therapeutics-to-present-at-the-2025-oppenheimer-innovation-on-the-island-biotech-summit-302417580.html
SOURCE Regulus Therapeutics Inc.